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pathetic activities ofbeta-adrenergic blo king agents and the 
use-dependent ffects of calcium channel blocking agents 
(verapamil and diltiazem) make these latter two classes of 
agents much more attractive for the control of ventricular 
rate. Guidelines for the appropriate combination f multiple 
pharmacologic agents for such control are not clearly estab- 
lished (46). Magnesium infusions have been shown to be 
capable ofprolonging AV node conduction, and the benefits 
of magnesium, both intravenously and on a chronic oral 
basis, warrant ~~vesti~at~o~ to determine if this cation weld 
be a useful adjunct to other measures for controlling ventric- 
ular rate (47). 
Catheter ablation of the AV junction using high energy 
direct current shocks was introduced in 1982 to control 
ventricular response rates to atrial tachyarrhythmia when 
this could not be accomplished by drug therapy or when the 
patient was intolerant of the drugs required to control 
utlusual circumstances. If, onversely, embolic events were 
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Further study is also needed to define the lowest dose of 
warfarin that provides effective stroke prophylaxis, particu- 
larly in the elderly. The relative ffectiveness of aspirin 
compared with warfarin for stroke prophylaxis must also be 
better understood. 
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